NCT00567554View on ClinicalTrials.gov

Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

2,600

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

August 31, 2011

Study Completion Date

October 31, 2015

Conditions
Breast Cancer
Interventions
DRUG

epirubicin - cyclophosphamide / docetaxel

DRUG

epirubicin - cyclophosphamide / docetaxel + bevacizumab

DRUG

paclitaxel

DRUG

paclitaxel + everolimus (RAD001)

DRUG

epirubicin - cyclophosphamide / docetaxel + trastuzumab

DRUG

epirubicin - cyclophosphamide / docetaxel + lapatinib

Trial Locations (1)

Unknown

Universitätsfrauenklinik Frankfurt / Main, Frankfurt am Main

All Listed Sponsors
collaborator

AGO Study Group

OTHER

lead

GBG Forschungs GmbH

OTHER

NCT00567554 - Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer | Biotech Hunter | Biotech Hunter